 |
|
|
| |
Patient Views on Long-Acting HIV Treatment: Cabotegravir + Rilpivirine as Maintenance Therapy (ATLAS 48-Week Results)
|
| |
| |
Reported by Jules Levin
10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico
M. Murray,1 A. Antela,2 A. Mills,3 V. Chounta,1 J. Huang,4 H. Jaeger,5
M.-A. Khuong-Josses,6 K. Hudson,7 W. Spreen,7 P. Williams,8 D. Margolis7
1ViiV Healthcare, Brentford, UK; 2Complejo Hospitalario Universitario de Santiago, La Coruña, Spain;
3Southern California Men's Medical Group, West Hollywood, CA, USA; 4GlaxoSmithKline, Mississauga, Ontario, Canada;
5MUC Research GmbH and MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany;
6Hôpital Delafontaine, Saint-Denis, France; 7ViiV Healthcare, Research Triangle Park, NC, USA, 8Janssen R&D, Beerse, Belgium Healthcare, Research Triangle Park, NC, USA, 8Janssen R&D, Beerse, Belgium
|
| |
|
|
|
|
|
